Real-World study tracks lupus drug anifrolumab in polish patients

NCT ID NCT06673043

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall health over time to see how well the treatment works in real-world settings. The goal is to better understand patient outcomes outside of controlled clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Bydgoszcz, Poland

  • Research Site

    RECRUITING

    Bytom, Poland

  • Research Site

    RECRUITING

    Gdansk, Poland

  • Research Site

    RECRUITING

    Katowice, Poland

  • Research Site

    RECRUITING

    Krakow, Poland

  • Research Site

    RECRUITING

    Lodz, Poland

  • Research Site

    RECRUITING

    Lublin, Poland

  • Research Site

    RECRUITING

    Poznan, Poland

  • Research Site

    RECRUITING

    Rzeszów, Poland

  • Research Site

    RECRUITING

    Warsaw, Poland

  • Research Site

    RECRUITING

    Wroclaw, Poland

Conditions

Explore the condition pages connected to this study.